Anonymous Family Firm Invests $30M In Seaside For Fragile X And Autism Research
This article was originally published in The Pink Sheet Daily
Executive Summary
Successor company to Sention hopes to create disease-modifying drugs for the two conditions.You may also be interested in...
Adventures in Glutamate: The Difficult and Expensive Path of Novelty in Drug Discovery
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Bayer/J&J's Xarelto Approval For Stroke Prevention Sets Up Marketing Battle With Pradaxa
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: